TCGA-66-2771-01A-01R-0980-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 60
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.560
- ALLOGRAFT_REJECTION+0.450
- MYC_TARGETS_V1+0.370
- FATTY_ACID_METABOLISM+0.340
- E2F_TARGETS+0.320
- IL6_JAK_STAT3_SIGNALING+0.320
- INTERFERON_GAMMA_RESPONSE+0.310
- MTORC1_SIGNALING+0.300
- INFLAMMATORY_RESPONSE+0.290
- DNA_REPAIR+0.200
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.550
- HEDGEHOG_SIGNALING-0.540
- TGF_BETA_SIGNALING-0.480
- MITOTIC_SPINDLE-0.440
- UV_RESPONSE_DN-0.410
- APICAL_JUNCTION-0.390
- NOTCH_SIGNALING-0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
- MYOGENESIS-0.310
- ANGIOGENESIS-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 2ad90ba0-8038-4bad-afa3-d176f63b42f0 | — | — | 0.876 |
| 2 | AUR-AERW-TTM1-A-1-1-R-A742-41 | — | C | 0.872 |
| 3 | SRR9879275 | — | cohortA1 | 0.865 |
| 4 | TCGA-05-5420-01A-01R-1628-07 | — | cohortA1 | 0.850 |
| 5 | AUR-AFUK-TTM1-A-1-0-R-A743-41 | — | B | 0.848 |
| 6 | 992ce1bc-46a2-4f57-ac7a-c6368c69c67c | — | — | 0.845 |
| 7 | TCGA-37-4130-01A-01R-1100-07 | — | cohortA1 | 0.842 |
| 8 | 20100231.Her2HRpos | — | C | 0.834 |
| 9 | TCGA-64-1677-01A-01R-0946-07 | — | cohortA1 | 0.832 |
| 10 | TCGA-D8-A1Y3-01A-11R-A157-07 | — | B | 0.829 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.560 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.340 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.320 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.320 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.310 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.290 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| COMPLEMENT | 0.190 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.180 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.180 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.160 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.150 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |